HMBD-001 is under clinical development by Hummingbird Bioscience and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase I drugs for Pancreatic Ductal Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the HMBD-001 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
HMBD-001 overview
HMBD-001 is under development for the treatment of solid tumors including esophageal squamous cell carcinoma (ESCC), squamous non-small cell lung carcinoma, metastatic castration resistant prostate cancer (mCRPC), bladder cancer, triple-negative breast cancer (TNBC), cervical cancer, colorectal cancer, endometrial cancer, gastric cancer, hepatocellular carcinoma, melanoma, non-small cell lung cancer, esophageal cancer, ovarian cancer, pancreatic cancer, pancreatic ductal adenocarcinoma and head and neck cancer squamous cell carcinoma and lung cancer. The therapeutic candidate is developed based on ONTarget, mAbPredict, mAbHits and mAbAdvance technologies. It acts by targeting receptor tyrosine protein kinase ERBB3 (HER3). It is administered through intravenous route. It is being developed based on Rational Antibody Discovery (RAD) platform.
Hummingbird Bioscience overview
Hummingbird Bioscience (Hummingbird) is a biotechnology company that discover and develops drugs to treat cancer, autoimmune diseases and infectious disorders. The company is investigating HMBD-001, an anti-HER3 neutralizing antibody to treat solid tumors; HMBD-002, an anti-vista neutralizing antibody for the treatment of cancer; and HMBD-004 for multiple myeloma. It is also evaluating COVID-19 mAb, a SARS-CoV-2 neutralizing antibody for the treatment of SARS-CoV-2 virus. Hummingbird employs its proprietary mAbPredict platform to provide rational antibody discovery that enables targeted identification and isolation of antibodies on a target protein and mAbHits platform that controls the immune system response to optimize the production of a higher number of antibodies against the desired epitopes. The company has operations in the US and Singapore. Hummingbird is headquartered in Singapore.
For a complete picture of HMBD-001’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.